Patents by Inventor Michael Damrat

Michael Damrat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC EGFR/CD16 ANTIGEN-BINDING PROTEIN
    Publication number: 20230190900
    Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.
    Type: Application
    Filed: October 19, 2022
    Publication date: June 22, 2023
    Inventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
  • Bispecific EGFR/CD16 antigen-binding protein
    Patent number: 11510972
    Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: November 29, 2022
    Assignee: AFFIMED GMBH
    Inventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
  • BISPECIFIC EGFR/CD16 ANTIGEN-BINDING PROTEIN
    Publication number: 20200405833
    Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 31, 2020
    Inventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Wanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder